Skip to main content
. Author manuscript; available in PMC: 2012 Dec 20.
Published in final edited form as: Gene Ther. 2011 Jun 30;19(1):78–85. doi: 10.1038/gt.2011.64

Figure 2. Re-administration of AAV8.

Figure 2

Figure 2

Figure 2

Figure 2

(A) Successful transduction with the same serotype of AAV. 2×1012/kg AAV8 CAGG IFNβ was given on day 100, 20 days later IFNβ levels were measured by ELISA (n=7, mean ±SEM). (B) Semi-quantitative PCR confirming selective transduction. 250ng of liver DNA from (n=2) CyA+Ab, NT (no immunosuppression), Naïve and IFN (hIFNβ only) cohorts were analysed with primers against hFIX, hIFNβ and βactin (C) Mice are not tolerised to capsid protein following transient immunosuppression. Anti-AAV8 abs were determined by ELISA on day 60 following 2nd administration n=6 mean ±SEM. (D) Mice were challenged with AAV8 LP1 hFX 5×1011/kg on day 296, 21 days later mice were bleed and FX levels were determined by ELISA n=3